Video
Dr. Siefker-Radtke discusses current research on the use of erdafitinib to treat urothelial carcinoma
Author(s):
"In a phase 2 clinical trial, we saw that erdafitinib had an objective response rate of around 40% in patients who received prior chemotherapy for their metastatic disease," says Dr. Siefker-Radtke.
Arlene O. Siefker-Radtke, MD, is a professor of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston. In this interview, Siefker-Radtke discusses the ongoing trials on the use of erdafitinib to treat FGFR3 altered urethelial cancers. She was interviewed during the 2022 LUGPA Annual Meeting in Chicago, Illinois.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Related Content
